Jefferies Maintains a 'Buy' on Amarin Corporation (AMRN); Incremental Positive Cardiologist Feedback

Jefferies maintains a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $24.00

Analyst, Thomas Wei, said, "While investor focus remains on securing favorable IP, we highlight in line but positive feedback from 9 cardiologists on AMR101. Feedback was encouraging on current CV utilization of omega-3s, differentiated LDL benefits of AMR101, and perception of fish oil safety. We remain bullish on AMR101 commercial prospects."

The Positives: Improved Positioning Relative To Fibrates And Niacin, Perceived
Safety Of Fish Oil, And Further Encouraging Feedback On Differentiated LDL
Profile.

The Negative: Physicians Highlight Increasing Importance Of CV Outcomes
Studies For Triglyceride Treatments.

Wei thinks the positive outweight the negatives and remains bullish on AMR101 and its potential outcomes

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $11.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Downgrades Calix (CALX) to Hold
• Meta Platforms Inc. (META) PT Lowered to $550 at Citi
• Sea Ltd. (SE) PT Raised to $85 at Jefferies; 'Solid Execution Across Different Segments'